Last reviewed · How we verify
Calcium-based phosphate binder
At a glance
| Generic name | Calcium-based phosphate binder |
|---|---|
| Also known as | Calcium carbonate, Calcium acetate |
| Sponsor | Genzyme, a Sanofi Company |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pentoxifylline on Inflammatory Markers in Non-Diabetic Chronic Kidney Disease Patients (NA)
- Activated Charcoal Use in Chronic Kidney Disease Patients (PHASE2)
- Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy (PHASE2, PHASE3)
- Assessing Bone Calcium Content in Children With Kidney Disease Treated With Two Different Medicines (NA)
- Effect of Lanthanum Carbonate in Patients Previously Treated With Calcium-based Phosphate Binder Therapy
- Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis (PHASE3)
- A Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent Chronic Kidney Disease (CKD) Patients With Hyperphosphataemia (PHASE3)
- Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Calcium-based phosphate binder CI brief — competitive landscape report
- Calcium-based phosphate binder updates RSS · CI watch RSS
- Genzyme, a Sanofi Company portfolio CI